Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P110009/S040

Mobi-C Cervical Disc Prosthesis for use at Two Levels

Highridge Medical, LLC · Decision date Sep 16, 2026

MEDTECHLEDGER EXPLANATIONP110009/S040

What did the FDA decide?

FDA recorded a 30-Day Notice decision coded OK30 on 2026-09-16 for supplement P110009/S040 to the Mobi-C® Cervical Disc Prosthesis for use at Two Levels, held by Highridge Medical, LLC. The supplement covers two manufacturing changes at the same Viant facility: adding CAM Bioceramics as a raw material supplier of hydroxyapatite powder used in coating the Mobi-C® inferior and superior endplates, and qualifying CeraTek sealing equipment for the final packaging pouch.

The recorded reason is a process change affecting manufacturer, sterilizer, packager or supplier, with device category intervertebral disc prosthesis, orthopedic specialty and product code MJO. This action concerns those supplier and equipment changes only; it is not a new approval of the whole disc system. The source lists no supporting documents, so the review basis and any conditions attached to the decision remain unknown.

Whether the new hydroxyapatite supplier or sealing equipment alters coating or package performance is not stated in the available record, and no clinical or legal conclusion follows from the OK30 code alone.

FDA approval order statement

addition of a new raw material supplier (CAM Bioceramics) for hydroxyapatite powder used in the coating of Mobi-C inferior and superior endplates, and qualification of a new sealing equipment (CeraTek) for sealing of the final packaging pouch of Mobi-C devices at the same Viant facility
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Orthopedic
Decision date
Sep 16, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P110009/S040
Regulatory pathway
PMA supplement
Product code
MJO
Decision code
OK30
Decision date
Sep 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, intervertebral disc.

Product code
MJO
FDA device class
3

For the original device and its historical approval scope, see PMA P110009. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P110009 · Original PMA

    MOBI-C CERVICAL DISC PROSTHESIS (TWO-LEVEL INDICATION)

  2. P110009/S040 received

    Application receipt date recorded by FDA.

  3. P110009/S040 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P110009. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P110009

Product / regulatory recordCompanyPathwayDecision dateSource
Highridge Medical, LLCPMA approvalAug 23, 2013FDA

Explore the linked device profile

Other records with product code MJO

Product / regulatory recordCompanyPathwayDecision dateSource
Spineart USA, Inc.PMA supplementSep 22, 2026FDA
Synergy DiscP250028/S003
Synergy Spine Solutions, Inc.PMA supplementSep 17, 2026FDA
Highridge Medical, LLCPMA supplementSep 16, 2026FDA
prodisc C NovaP070001/S031
Centinel Spine, LLCPMA supplementSep 9, 2026FDA
Spineart USA, Inc.PMA approvalAug 10, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Highridge Medical, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
10225 Westmoor Dr., Westminister, CO, 80021

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records